This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers (CMSC), to serve as an educational guide and concise summary of available data and professional recommendations on the selection of disease-modifying therapy (DMT) for MS. The group met in Chicago, IL, in 2018 at a conference independently sponsored by the CMSC to discuss and debate current concepts on DMT use.
2019 CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis
Related Posts
Comments are closed.